Amicus Therapeutics, Inc. Announces Revenue Results for the Full Year of 2017; Provides Revenue Guidance for the Full Year of 2018
January 08, 2018 at 07:30 am
Share
Amicus Therapeutics, Inc. announced revenue results for the full year of 2017. For the year, the company reported revenue of $36 million from commercial sales and reimbursed expanded access programs for Galafold.
For the full year of 2018, the company expects total Galafold revenue of $75 million to $85 million.
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
AMICUS THERAPEUTICS, INC. 
